Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma.
about
Biomarkers and prognostic factors for mesotheliomaVariation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapyIdentification of a 5-gene signature for clinical and prognostic prediction in gastric cancer patients upon microarray data.Second generation sequencing of the mesothelioma tumor genome.Genes associated with prognosis after surgery for malignant pleural mesothelioma promote tumor cell survival in vitro.Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee.Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesotheliomaRatio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma.Forward genetic screens in mice uncover mediators and suppressors of metastatic reactivation.Fine-needle aspiration biopsies for gene expression ratio-based diagnostic and prognostic tests in malignant pleural mesotheliomaAnalysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma.Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know.Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma.Validation of a gene expression test for mesothelioma prognosis in formalin-fixed paraffin-embedded tissuesChemotherapy for malignant pleural mesothelioma: a review of current management and a look to the futureBiomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application.Gene expression ratio test distinguishes normal lung from lung tumors in solid tissue and FNA biopsies.Making the case for molecular staging of malignant pleural mesothelioma.Surgery for malignant pleural mesothelioma.Diagnostic molecular biomarkers for malignant pleural effusions.Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.Biomarkers and prognostic factors for malignant pleural mesothelioma.Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles.Changes in PKM2 associate with prostate cancer progression.Clinical staging of malignant pleural mesothelioma: current perspectives.PKM2, a Central Point of Regulation in Cancer Metabolism.Factors predicting poor survival after lung-sparing radical pleurectomy of IMIG stage III malignant pleural mesothelioma.Cobl-like promotes actin filament formation and dendritic branching using only a single WH2 domain.Pyruvate kinase M2 fuels multiple aspects of cancer cells: from cellular metabolism, transcriptional regulation to extracellular signaling.Overexpressed genes in malignant pleural mesothelioma: implications in clinical management.COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.
P2860
Q28387194-2BC6CF8A-5323-4D1B-8744-392F98E0B0E8Q28534042-3336CB89-99D4-41DB-A568-674602B387E1Q30659104-3C2D1295-95C9-4B2D-B1DE-EDAB0D72B1DFQ33582141-A68C887A-33BB-4A41-96D4-8B5A51067D12Q33899105-E721C14D-5723-4665-AE64-830DE6A345F9Q34041728-090D2D08-D864-43CE-B45E-914E3902C1AFQ34060193-C7056CBA-1C2E-4B69-92DA-8C1A261AF1A9Q34142500-2F3BC863-78C5-4C71-AE44-60539F801A69Q34581396-B5BFA95B-A5A1-40B3-9C4F-DEA6F932DDBEQ34679620-264A02D3-53AF-4EBC-A6B1-1E5419FCD293Q35959234-77AEF4C3-F3D1-4B56-8C29-9DF393BA33E1Q35997395-35240835-0DD8-4041-8C16-414F95C77B57Q36815218-E69E2D42-A0EC-42FD-A626-ADC9AEAB2CA1Q36887990-72C2E8B9-A119-4C64-BADE-0B028F75FF03Q37090808-20858543-3838-43FE-8644-801731E0310DQ37328307-74A47E85-2EEA-498D-8CD6-E4092FD13AD5Q37608246-65DE456D-A952-4EEA-9AB9-787649CB4424Q37613240-8A33E679-D0B6-4798-A4F0-DF033A5FB8C1Q37762833-8BD104A1-F560-4301-A631-F8BAB5266520Q37889963-DD52F32F-BA71-4E01-9407-5287B0CBA9E6Q38119922-B8AA2712-D2C9-44A7-ADEC-EACEE5BF3FD8Q38660038-F0345514-3FAB-4ECF-92F3-7DF82CB83B72Q38972707-9B3BC9C2-B1A4-4697-B903-C8A5B46A4F1FQ38989500-F2BF90B2-7197-44B1-A435-7A1E543D3C0BQ41522440-D58BBE10-7B54-4FA2-9D1D-5C56ED2C9B95Q41669982-8CF180C6-413B-4F09-A0A5-C7D7212DE56DQ43512869-40B93456-EDF9-428F-B967-4B20F3D24EF1Q47301201-5A784102-F7B0-4527-9143-FBE2B7811445Q49888029-3AE81810-79B3-4034-A6BA-2F95080CD31FQ52672878-7320E8FE-D0C1-47EB-A19A-370C629055DDQ53098391-D317A922-E1C5-45D9-B6D2-14207370C5E5
P2860
Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Four-gene expression ratio tes ...... oing surgery for mesothelioma.
@en
Four-gene expression ratio tes ...... oing surgery for mesothelioma.
@nl
type
label
Four-gene expression ratio tes ...... oing surgery for mesothelioma.
@en
Four-gene expression ratio tes ...... oing surgery for mesothelioma.
@nl
prefLabel
Four-gene expression ratio tes ...... oing surgery for mesothelioma.
@en
Four-gene expression ratio tes ...... oing surgery for mesothelioma.
@nl
P2093
P2860
P356
P1476
Four-gene expression ratio tes ...... oing surgery for mesothelioma.
@en
P2093
Beow Y Yeap
Branden Van Oss
Gautam Maulik
Gavin J Gordon
Heather Edenfield
Jonathan N Glickman
Lingsheng Dong
Madhubalan Mani
Raphael Bueno
Richard Colquitt
P2860
P304
P356
10.1093/JNCI/DJP061
P407
P577
2009-04-28T00:00:00Z